Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Observational, Prospective Registry of Participants With Sickle Cell Disease (SCD) Treated With Oxbryta® (Voxelotor)

NCT04930445 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04930445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04930445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Observational, Prospective Registry of Participants With Sickle Cell Disease (SCD) Treated With Oxbryta® (Voxelotor)
Lead sponsor
Pfizer
Phase
Observational
Overall status
Terminated
Start date
February 4, 2022
Completion date
October 10, 2024
Enrollment
265 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease